Key result
Thrombolytic therapy was associated with significantly lower in-hospital mortality compared to no therapy in patients with massive pulmonary thromboembolism (p=0.022).
Why the study?
Acute pulmonary thromboembolism carries high mortality, motivating an evaluation of its clinical presentation and management in the Indian population.
Does thrombolysis reduce in-hospital mortality in patients with acute pulmonary thromboembolism?
Observational (n=140)
No
Does thrombolysis reduce in-hospital mortality in patients with acute pulmonary thromboembolism?
p-value: p=0.022
In an Indian cohort, acute pulmonary thromboembolism presents at a younger age and is associated with high mortality, which is significantly reduced by thrombolysis in massive PE.
Provides regional epidemiological context for pulmonary embolism presentation and management; leaves open whether these demographic patterns warrant.
Acute pulmonary thromboembolism is associated with high mortality, similar to that of myocardial infarction and stroke. We studied the clinical presentation and management of pulmonary thromboembolism in the Indian population. An analysis of 140 patients who presented with acute pulmonary thromboembolism at a large volume center in India from June 2015 through December 2018 was performed. The mean age of our study population was 50 years with 59% being male. Comorbidities including deep vein thrombosis, diabetes mellitus, hypertension, and chronic obstructive pulmonary disease were present in 52.9%, 40%, 35.7% and 7.14% of patients, respectively. Out of 140 patients, 40 (28.6%) patients had massive pulmonary thromboembolism, 36 (25.7%) sub‐massive pulmonary thromboembolism, and 64 (45.7%) had low‐risk pulmonary thromboembolism. Overall, in‐hospital mortality was 25.7%. Multivariate regression analysis found chronic kidney disease and pulmonary thromboembolism severity to be the only independent risk factors. Thrombolysis was performed in 62.5% of patients with a massive pulmonary thromboembolism and 63.9% of patients with a sub‐massive pulmonary thromboembolism. In the massive pulmonary thromboembolism group, patients receiving thrombolytic therapy had lower mortality compared with patients who did not receive therapy (p=0.022), whereas this difference was not observed in patients in the sub‐massive pulmonary thromboembolism group. We conclude that patients with acute pulmonary thromboembolism in India presented more than a decade earlier than our western counterparts, and it was associated with poor clinical outcomes. Thrombolysis was associated with significantly reduced in‐hospital mortality in patients with massive pulmonary thromboembolism.
No takes yet. Share an insight, caveat, or question.
Muralidharan et al. (2021) conducted an observational in Acute pulmonary thromboembolism (n=140). Thrombolytic therapy vs. No thrombolytic therapy was evaluated on In-hospital mortality (p=0.022). Thrombolytic therapy was associated with significantly lower in-hospital mortality compared to no therapy in patients with massive pulmonary thromboembolism (p=0.022).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: